Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction

被引:258
作者
Garratt, KN [1 ]
Brady, PA [1 ]
Hassinger, NL [1 ]
Grill, DE [1 ]
Terzic, A [1 ]
Holmes, DR [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
D O I
10.1016/S0735-1097(98)00557-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The purpose of this study was to examine the impact of sulfonylurea drug use on outcome in diabetic patients undergoing direct coronary angioplasty for acute myocardial infarction. Background. Sulfonylurea drugs impair ischemic preconditioning. Whether sulfonylurea drugs affect outcome adversely in diabetic patients undergoing direct angioplasty for acute myocardial infarction is unknown. Methods. Clinical outcomes after direct balloon angioplasty for acute myocardial infarction were evaluated in 67 diabetic patients taking oral sulfonylurea drugs and 118 diabetic patients not taking these drugs. Results. Hospital mortality was significantly higher among diabetics treated with sulfonylurea drugs at the time of myocardial infarction (24% vs. 11%). Univariate analysis identified sulfonylurea drug, age, ventricular function, ejection fraction less than 40%, prior bypass surgery and congestive heart failure as correlates of increased in-hospital mortality. Logistic regression found sulfonylurea drug use (odds ratio 2.77, p = 0.017) to be independently associated with early mortality. Congestive heart failure, but not sulfonylurea drug use, was associated with an increased incidence of in-hospital ventricular arrhythmias. Congestive heart failure, prior bypass surgery and female gender, but not sulfonylurea drug use, were associated with late adverse events. Conclusions. Sulfonylurea drug use is associated with an increased risk of in hospital mortality among diabetic patients undergoing coronary angioplasty for acute myocardial infarction. This early risk is not explained by an increase in ventricular arrhythmias, but may reflect deleterious effects of sulfonylurea drugs on myocardial tolerance for ischemia and reperfusion. For surviving patients sulfonylurea drug use is not associated with an increased risk of serious late adverse events. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:119 / 124
页数:6
相关论文
共 46 条
  • [1] EFFECT OF DIABETES-MELLITUS ON SHORT-TERM AND LONG-TERM MORTALITY-RATES OF PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A STATEWIDE STUDY
    ABBUD, ZA
    SHINDLER, DM
    WILSON, AC
    KOSTIS, JB
    [J]. AMERICAN HEART JOURNAL, 1995, 130 (01) : 51 - 58
  • [2] Alderman EL, 1996, NEW ENGL J MED, V335, P217
  • [3] Thrombosis in ischemic heart disease
    Ambrose, JA
    Weinrauch, M
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (13) : 1382 - 1394
  • [4] THE SULFONYLUREA RECEPTOR
    ASHCROFT, SJH
    ASHCROFT, FM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1175 (01) : 45 - 49
  • [5] Dual effect of glyburide, an antagonist of K-ATP channels, on metabolic inhibition-induced Ca2+ loading in cardiomyocytes
    Brady, PA
    Zhang, SC
    Lopez, JR
    Jovanovic, A
    Alekseev, AE
    Terzic, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 308 (03) : 343 - 349
  • [6] The sulfonylurea controversy: More questions from the heart
    Brady, PA
    Terzic, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (05) : 950 - 956
  • [7] Brady PA, 1998, CIRCULATION, V97, P709
  • [8] Brady PA, 1998, CIRC RES, V82, P272
  • [9] A disrupter of actin microfilaments impairs sulfonylurea-inhibitory gating of cardiac K-ATP channels
    Brady, PA
    Alekseev, AE
    Aleksandrova, LA
    Gomez, LA
    Terzic, A
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 271 (06): : H2710 - H2716
  • [10] Cleveland JC, 1997, CIRCULATION, V96, P29